ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Optimizing Treatment Selection for HER2+ Breast Cancer Patients with Brain Metastases "
Episode Synopsis
CME credits: 1.00
Valid until: 18-06-2026
Claim your CME credit at https://reachmd.com/programs/cme/optimizing-treatment-selection-for-her2-breast-cancer-patients-with-brain-metastases/29950/
The development and availability of HER2-directed therapies has dramatically improved outcomes for patients with metastatic breast cancer (MBC). Moreover, emerging data indicate that these therapies also improve outcomes for those with brain metastasis. In this educational series, expert faculty differentiate the available HER2-directed therapies for MBC, assess their efficacy in disease with brain metastasis, and review treatment selection and sequencing considerations for these agents.
Valid until: 18-06-2026
Claim your CME credit at https://reachmd.com/programs/cme/optimizing-treatment-selection-for-her2-breast-cancer-patients-with-brain-metastases/29950/
The development and availability of HER2-directed therapies has dramatically improved outcomes for patients with metastatic breast cancer (MBC). Moreover, emerging data indicate that these therapies also improve outcomes for those with brain metastasis. In this educational series, expert faculty differentiate the available HER2-directed therapies for MBC, assess their efficacy in disease with brain metastasis, and review treatment selection and sequencing considerations for these agents.
More episodes of the podcast ReachMD CME
The Fifth Pillar? Closing the Gap in HFrEF
14/11/2025
In God we trust